A Phase I, Single Ascending and Multiple Ascending Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LIFE-001
Latest Information Update: 21 May 2025
At a glance
- Drugs LIFE 001 (Primary)
- Indications Immunological disorders; Transplant rejection
- Focus Adverse reactions
- Sponsors LifeMine Therapeutics
Most Recent Events
- 13 May 2025 Status changed from not yet recruiting to recruiting.
- 14 Apr 2025 New trial record